Princess® RICH for the Correction of Fine Lines
- Conditions
- Lateral Canthal LinesPerioral Rhytids
- Interventions
- Device: Princess® RICH
- Registration Number
- NCT03923634
- Lead Sponsor
- Croma-Pharma GmbH
- Brief Summary
Eligible subjects deemed by the treating physician to have sufficient severity to merit treatment of either their lateral canthal lines (LCL) or perioral rhytids (PR) or both will be treated with Princess® RICH at the Baseline visit and at week 3 and 6.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 102
- Subjects deemed by the treating physician to have LCL and/or PR of sufficient baseline severity to merit treatment with Princess® RICH to be corrected
- A negative urine pregnancy test at Visit 1 and commitment to use an adequate method of birth control for the duration of the clinical investigation (for women of childbearing potential only.)
- Healthy skin in the facial area and free of diseases that could interfere in cutaneous aging evaluation
- Willingness to abstain from any aesthetic or surgical procedures in the treatment area for the duration of the clinical investigation
- Written signed and dated informed consent
- Tendency to hypertrophic scars, pigment disorders or keloid formation.
- History of autoimmune disease or receiving therapy for modification of immune response
- Hypersensitivity to hyaluronic acid or glycerol.
- Permanent fillers in the areas to be treated.
- Subjects who are pregnant or breast feeding.
- Subjects who are anticoagulated or with history of bleeding disorder.
- Daily treatment with platelet aggregation inhibitors unless previously cleared by their primary care physician.
- Cutaneous, inflammatory and/or infectious processes present at V0, recurrent herpes simplex or (pre) cancerous lesions in the areas to be treated
- Known Diabetes mellitus or uncontrolled systemic diseases in the assessment of the investigator.
- Laser therapy, chemical peeling, dermabrasion or botulin toxin treatment in the area to be treated within less than three months prior to and during the course of the study.
- Current participation in another clinical investigation
- Subjects whose participation in clinical trials is prohibited by the Austrian Medical Devices Act (e.g, persons with a legal custodian appointed due to mental disability, prisoners, soldiers and other members of the armed forces, civil servants)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Princess® RICH Princess® RICH Eligible subjects will be injected with Princess® RICH (this is an open-label study). Princess® RICH is injected into the lateral canthal lines and/or perioral rhytids.
- Primary Outcome Measures
Name Time Method Effectiveness of Princess® RICH to correct fine lines on the face including lateral canthal lines (LCL) and perioral rhytids (PR) Week 8 compared to Baseline Percentage of responders at week 8 Responder is defined as at least "improved" versus baseline in the fine lines of lateral canthal lines (LCL) and/or perioral rhytids (PR) assessed with the GAIS (Gloabel Aesthetic Improvement Scale)
Global aesthetic improvement can be rated as 'very much improved', 'much improved', 'improved', 'no change' or 'worse
- Secondary Outcome Measures
Name Time Method Effectiveness of Princess® RICH to correct fine lines on the face including lateral canthal lines (LCL) and perioral rhytids (PR) Week 12 and 16 compared to Baseline Percentage of responders at week 12 and 16.
Ability of Princess® RICH to improve skin hydration Week 3, 6, 8, 12 and 16 compared to Baseline Change from baseline at weeks 3, 6, 8, 12 and 16 in skin hydration. Skin hydration is measured using a corneometer device.
Ability of Princess® RICH to improve skin tone Week 3, 6, 8, 12 and 16 compared to Baseline Changes from baseline at weeks 3, 6, 8, 12 and 16 in skin tone. Skin tone is measured using a cutometer device.
Ability of Princess® RICH to improve skin elasticity Week 3, 6, 8, 12 and 16 compared to Baseline Change from baseline at weeks 3, 6, 8, 12 and 16 in skin elasticity. Skin elasticity is measured using a cutometer device.
Subject satisfaction with treatment Week 8, 12 and 16 Subject satisfaction with treatment at weeks 8, 12 and 16. Satisfaction with the treatment will be graded using one of the following categories: "Very unsatisfied", "Unsatisfied", "Neither unsatisfied nor satisfied", "Satisfied", or "Very satisfied".
Trial Locations
- Locations (3)
MaRa-Medical Aesthetic Research Academy
🇦🇹Graz, Austria
YUVELL
🇦🇹Vienna, Austria
Medizinische Universität-Klinikum für Dermatologie und Venerologie
🇦🇹Graz, Austria